Telephone interviews to deliver genetic counseling may be non-inferior to in-person counseling.
Several adjuvant endocrine therapy options are available for premenopausal patients with endocrine-responsive early-stage breast cancer.
New biomarkers might revolutionize prostate cancer treatment, according to an educational presentation at the 2016 ASCO Annual Meeting in Chicago.
Local treatment may provide a survival benefit for patients with metastatic non-small cell lung cancer (NSCLC).
At the 2016 ASCO Annual Meeting, presenters discussed the current state and future of immune therapy for patients with head and neck cancer.
Some patients with rectal cancer who experience complete clinical response after neoadjuvant therapy may safely avoid total mesorectal excision.
Harvard researchers are developing a machine-learning algorithm, using a "deep learning" approach, which interprets complex patterns observed in real-life data by building multi-layered artificial neural networks, in an attempt to refine AI-based cancer diagnoses.
Oncologists may be on the path towards elucidating clinically translatable etiologies of MM.
Access to chemotherapy is just 1 of many factors influencing disparities of survival rates among men and women diagnosed with bladder cancer.
A combination of radiotherapy with local and systemic immunotherapy may be clinically beneficial for treating some types of tumors.
Several novel agents, including checkpoint inhibitors, are being tested and may soon be approved for the treatment of metastatic breast cancer.
Calls for wider adoption of surrogate survival measures as clinical trial endpoints should be considered cautiously; physicians should carefully consider—and communicate to patients—clinical trials' endpoints.
Males with breast cancer are less likely to survive than females after disease recurrence, which may be due to less aggressive treatment after relapse.
Patients with ALL treated with the monoclonal antibody inotuzumab ozogamicin were more likely to proceed to stem cell transplantation.
A cross-sectional study of treatments for MM across several European countries suggests consistency in agents used as first-line and second-line treatments, though there are disparities among later treatments.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Era of Precision Oncology for Prostate Cancer 'Is Upon Us'
- Veliparib and Carboplatin May Be Effective Against Triple-negative Breast Cancer
- Metastatic Prostate Cancer Cases On the Rise in the U.S.
- Some Patients With Locally Advanced Rectal Cancer May Avoid Surgery
- Some Patients With Endocrine-responsive Early-stage Breast Cancer May Avoid Chemotherapy
- Multiple Myeloma May Be Linked to Pesticide Exposure
- Immune Therapies May Offer Promise for Hormone-receptor-positive Breast Cancer
- First-line Nivolumab Plus Platinum-based Doublet Active in Advanced NSCLC
- Senescent Effects on Cancer Cells Are Context-dependent
- Breast-conserving Surgery and Radiotherapy May Provide Better Overall Survival Than Mastectomy
- Life Expectancy of Patients With CML Greatly Improved, but at What Cost?
- Costs of Malignant Blood Disorders in European Countries Reached €23 Billion in 2012
- Achieving Negative Margin Essential for Optimizing Local Control, Survival in Sarcoma
- Is BRCA1/2 Genetic Counseling by Telephone Inferior to a Face-to-face Interaction?
- FDA Declines to Approve Pegfilgrastim Biosimilar